Bellicum boosted on beta thalassemia update; Almac creates 180 new jobs;

@FierceBiotech: ICYMI yesterday: Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Old ACT was always reliable. Every fresh bit of data was a revolutionary breakthrough. But never got out of early stage R&D. | Follow @JohnCFierce

@DamianFierce: "I can't believe the future is sending feces around the country," said $MCBM's CEO, having never heard of Twitter. More from the NYT | Follow @DamianFierce

> Shares of Bellicum Pharmaceuticals ($BLCM) got an after-market boost Monday evening after the biotech noted that all four of the children suffering from beta thalassemia major were blood-transfusion independent within two weeks of being treated with BPX-501 engineered T cells. Release

> Almac is creating 180 new jobs at an old facility in Northern Ireland that once belonged to AstraZeneca. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Google Life Sciences teams with AHA to target heart disease in $50M research initiative. Article | Follow @FierceMedDev

@VarunSaxena2: JAMA study: Rate of inappropriate stenting is declining. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists make strides toward full-body PET scanner with $15.5M in tow. Article | Follow @EmilyWFierce

> IBM brings Watson to Boston Children's Hospital for rare pediatric disease diagnosis. News

> FDA cracks down on genetic test makers for direct-to-consumer marketing. Report

Pharma News

@FiercePharma: Luye's schizophrenia drug gets nod to move ahead with NDA approval. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: | Follow @EricPFierce

@CarlyHFierce: $VRX "working hard" to reach out to payers, CEO says. "Historically, I have not spent a lot of time doing that." | Follow @CarlyHFierce

> Short-seller Citron spotlights Mallinckrodt as 'worse offender' than Valeant. Report

> J&J slapped with $1.8M verdict in Risperdal breast growth case. Article

Drug Delivery News

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Report

> Canadian doctor opens blood-brain barrier using focused ultrasound. Item

> Ebola study will monitor viral entry into cells, with focus on drug delivery. Story

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Article

> GSK beats AstraZeneca to finish line, wins FDA approval of first anti-IL-5 injectable for asthma. More

Pharma Manufacturing News

> Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy. Story

> Pfizer recalls 21,000 bottles of Xanax that may be too weak. More

> Almac expanding in U.K., investing $24M in Charnwood tech park. Report

> Dr. Reddy's gets slapped with FDA warning letter for three Indian plants. Article

> Sun's U.S. sales crater as plant issues cut deeply. Story

Pharma Asia News

> AstraZeneca shows more solid gains in China on respiratory. More

> Luye's schizophrenia drug gets nod to move ahead with NDA approval. Story

> China to restart mainland IPOs, with pharma ready to roll. Item

> FDA widens review of Dr. Reddy's manufacturing ops. More

> India's Sun Pharmaceutical takes another Ranbaxy-related hit. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.